Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms

Detalhes bibliográficos
Autor(a) principal: Reis, SS
Data de Publicação: 2019
Outros Autores: Carvalho, AS, Fernandes, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/136228
Resumo: Tamoxifen is a drug that is often used in the clinical management of breast cancer. CYP2D6 is a key metabolizing enzyme that is involved in the conversion of tamoxifen to its active drug metabolites. CYP2D6 has several alleles that metabolize tamoxifen and other drugs at different rates that can alter therapeutic impact, a characteristic that renders it one of the most studied enzymes in the field of pharmacogenetics. Background and objectives: Portugal has no implemented measures based on pharmacogenomics analysis prior to therapy that might function as a cultural sample control when analyzing the individual and economic factors present in clinical practice paradigms. Therefore, we aim to investigate the impact of CYP2D6 genotyping of the tamoxifen metabolizing enzymes in the clinical management of breast cancer patients. Materials and Methods: Qualitative/quantitative studies regarding the impact of pharmacogenomics in breast cancer; personal interviews in different Portuguese laboratories within hospital setting using a survey. Analysis of data through interviews to management board and/or decision makers from major oncological centers. Results: Reasons for common adoption of pharmacogenomics practice are contradictory and based both in economic factors and cultural/clinical bias. Conclusions: This research study identifies specific cultural and/or clinical bias that act as obstacles to pharmacogenomic implementation and proposes viable courses of action that might bring about change in cultural/medical habits.
id RCAP_0654caebfd2d9ea19faae213359b2b78
oai_identifier_str oai:repositorio-aberto.up.pt:10216/136228
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigmsBreast cancerClinical biasClinical policiesCultural sample controlCYP2D6Hormone therapyPharmacogenomicsTamoxifenTamoxifen is a drug that is often used in the clinical management of breast cancer. CYP2D6 is a key metabolizing enzyme that is involved in the conversion of tamoxifen to its active drug metabolites. CYP2D6 has several alleles that metabolize tamoxifen and other drugs at different rates that can alter therapeutic impact, a characteristic that renders it one of the most studied enzymes in the field of pharmacogenetics. Background and objectives: Portugal has no implemented measures based on pharmacogenomics analysis prior to therapy that might function as a cultural sample control when analyzing the individual and economic factors present in clinical practice paradigms. Therefore, we aim to investigate the impact of CYP2D6 genotyping of the tamoxifen metabolizing enzymes in the clinical management of breast cancer patients. Materials and Methods: Qualitative/quantitative studies regarding the impact of pharmacogenomics in breast cancer; personal interviews in different Portuguese laboratories within hospital setting using a survey. Analysis of data through interviews to management board and/or decision makers from major oncological centers. Results: Reasons for common adoption of pharmacogenomics practice are contradictory and based both in economic factors and cultural/clinical bias. Conclusions: This research study identifies specific cultural and/or clinical bias that act as obstacles to pharmacogenomic implementation and proposes viable courses of action that might bring about change in cultural/medical habits.MDPI20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/136228eng1010-660X10.3390/medicina55070344Reis, SSCarvalho, ASFernandes, Rinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:24:53Zoai:repositorio-aberto.up.pt:10216/136228Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:23:06.087430Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
title Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
spellingShingle Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
Reis, SS
Breast cancer
Clinical bias
Clinical policies
Cultural sample control
CYP2D6
Hormone therapy
Pharmacogenomics
Tamoxifen
title_short Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
title_full Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
title_fullStr Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
title_full_unstemmed Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
title_sort Pharmacogenomics, CYP2D6, and tamoxifen: A survey of the reasons sustaining european clinical practice paradigms
author Reis, SS
author_facet Reis, SS
Carvalho, AS
Fernandes, R
author_role author
author2 Carvalho, AS
Fernandes, R
author2_role author
author
dc.contributor.author.fl_str_mv Reis, SS
Carvalho, AS
Fernandes, R
dc.subject.por.fl_str_mv Breast cancer
Clinical bias
Clinical policies
Cultural sample control
CYP2D6
Hormone therapy
Pharmacogenomics
Tamoxifen
topic Breast cancer
Clinical bias
Clinical policies
Cultural sample control
CYP2D6
Hormone therapy
Pharmacogenomics
Tamoxifen
description Tamoxifen is a drug that is often used in the clinical management of breast cancer. CYP2D6 is a key metabolizing enzyme that is involved in the conversion of tamoxifen to its active drug metabolites. CYP2D6 has several alleles that metabolize tamoxifen and other drugs at different rates that can alter therapeutic impact, a characteristic that renders it one of the most studied enzymes in the field of pharmacogenetics. Background and objectives: Portugal has no implemented measures based on pharmacogenomics analysis prior to therapy that might function as a cultural sample control when analyzing the individual and economic factors present in clinical practice paradigms. Therefore, we aim to investigate the impact of CYP2D6 genotyping of the tamoxifen metabolizing enzymes in the clinical management of breast cancer patients. Materials and Methods: Qualitative/quantitative studies regarding the impact of pharmacogenomics in breast cancer; personal interviews in different Portuguese laboratories within hospital setting using a survey. Analysis of data through interviews to management board and/or decision makers from major oncological centers. Results: Reasons for common adoption of pharmacogenomics practice are contradictory and based both in economic factors and cultural/clinical bias. Conclusions: This research study identifies specific cultural and/or clinical bias that act as obstacles to pharmacogenomic implementation and proposes viable courses of action that might bring about change in cultural/medical habits.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/136228
url https://hdl.handle.net/10216/136228
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1010-660X
10.3390/medicina55070344
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136146847956993